Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on oncology, with an emphasis on treatments for hematological malignancies, that reached public markets through its merger with LifeSci Acquisition Corp., a blank-check company sponsored by LifeSci SPAC Holdings LLC that completed its IPO in 2020. The de-SPAC combination closed in early 2021, listing the combined entity on Nasdaq under the VINC ticker. The company submitted an 8-K current report to the SEC on March 18, 2025, bearing accession number 0001193125-25-056229. Sign up at SpacDesk to access full filing histories, sponsor profiles, and transaction analytics across the entire SPAC universe.